CompletedPhase 1

Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

Sweden11 participantsStarted 2019-08-08

Plain-language summary

This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. patient ages 18 to 40 years.
✓. a duration of illness exceeding 2 years.
✓. correspond to "Markedly ill", "Severely ill" or "Among the most extremely ill patients" on the Clinical Global Impression - Severity scale (CGI-S).
✓. Global Assessment of Functioning (GAF) below 50.
✓. obsessive-compulsive disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
✓. treatment resistance, i.e. failing to remit despite adequate treatments.
✓. if female and with any risk for pregnancy, willing to use contraceptives.
✓. if psychotropic treatment is prescribed the plasma concentrations of the drug must be tested and shown to be within therapeutic interval.

Yale-Brown obsessive- compulsive scale (Y-BOCS)

Timeframe: week 20

NCT IDNCT03983031

SponsorRegion Örebro County

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-31